Home

Calidi Biotherapeutics, Inc. Common Stock (CLDI)

0.9980
+0.2980 (42.57%)
NYSE · Last Trade: Jul 11th, 12:35 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.7000
Open0.7300
Bid0.8756
Ask0.8800
Day's Range0.6600 - 1.100
52 Week Range0.2027 - 3.890
Volume117,263,514
Market Cap31.73M
PE Ratio (TTM)-0.6012
EPS (TTM)-1.7
Dividend & YieldN/A (N/A)
1 Month Average Volume38,749,739

Chart

News & Press Releases

12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · July 10, 2025
Top movers in Thursday's after hours sessionchartmill.com
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 10, 2025
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 10, 2025
Curious about the most active stocks on Thursday?chartmill.com
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active stocks in today's session.
Via Chartmill · July 10, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · July 10, 2025
In today's session, these stocks are experiencing unusual volume.chartmill.com
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · July 10, 2025
Which stocks are experiencing notable movement on Thursday?chartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · July 10, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds to support its clinical and pre-clinical programs, operations and working capital.
Via Investor Brand Network · July 10, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
By Calidi Biotherapeutics Inc. · Via GlobeNewswire · July 10, 2025
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 9, 2025
Which stocks are most active on Wednesday?chartmill.com
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Via Chartmill · July 9, 2025
Crude Oil Moves Higher; RxSight Shares Plungebenzinga.com
Via Benzinga · July 9, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · July 9, 2025
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In Maybenzinga.com
Via Benzinga · July 9, 2025
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage : Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades. By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX) , Crispr Therapeutics AG (NASDAQ: CRSP) and…
Via Investor Brand Network · July 9, 2025
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END
Via FinancialNewsMedia · July 9, 2025
These stocks are moving in today's pre-market sessionchartmill.com
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · July 9, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 9, 2025
US Stocks Likely To Open Higher: Trump's Tariff Clock Ticks, Fed Likely To Keep Rates Unchangedbenzinga.com
U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were trading higher.
Via Benzinga · July 9, 2025
Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarketbenzinga.com
Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest.
Via Benzinga · July 9, 2025
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going Onbenzinga.com
Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.
Via Benzinga · July 9, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · July 8, 2025
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.
Via Investor Brand Network · July 8, 2025
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.
Via Investor Brand Network · July 8, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
By Calidi Biotherapeutics Inc. · Via GlobeNewswire · July 8, 2025